Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide
- 20 October 2004
- journal article
- research article
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 58 (9) , 833-837
Abstract
Cardiovascular mortality and morbidity are increased in patients with type 2 diabetes. However, there are few data from clinical trials comparing cardiovascular effects of alternative oral anti‐diabetic agents. Major cardiovascular outcomes during four one‐year, double‐blind trials in over 3700 patients with type 2 diabetes randomised to either a thiazolidinedione, pioglitazone, metformin or a sulphonylurea, gliclazide treatment have been combined. Mean blood pressure was slightly reduced by all treatments, with pioglitazone treatment resulting in the largest falls (approximately 1.5 mmHg). Hospitalisations for cardiac or cerebrovascular events were similar with the different treatments. Overall mortality was seven of 1857 for pioglitazone and 10 of 1856 for non‐pioglitazone treatments, of which three and six were cardiac deaths, respectively. The incidence of congestive cardiac failure was similar with pioglitazone (12/1857) and non‐pioglitazone (10/1856) treatments. The results show similar cardiovascular outcome for the three different treatments over a one‐year period, but demonstrate interesting differences, which will require longer‐term formal outcome studies to determine their significance.Keywords
This publication has 9 references indexed in Scilit:
- Thiazolidinedione Use, Fluid Retention, and Congestive Heart FailureDiabetes Care, 2004
- Thiazolidinediones and Blood Lipids in Type 2 DiabetesArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Thiazolidinedione Safety and Efficacy in Ambulatory Patients Receiving HemodialysisPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- Effects of Pioglitazone in Nondiabetic Patients with Arterial Hypertension: A Double-Blind, Placebo-Controlled StudyThe Journal of Clinical Endocrinology & Metabolism, 2002
- Insulin Resistance and Endothelial Dysfunction in Atherosclerosis: Implications and InterventionsDiabetes Technology & Therapeutics, 2002
- Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targetsJournal of Diabetes and its Complications, 2002
- Update on the cardiometabolic syndromeClinical Cornerstone, 2001
- PioglitazoneDrugs, 2000
- Direct Vasodepressor Effects of Pioglitazone in Spontaneously Hypertensive RatsPharmacology, 1998